Analysis of tumor burden versus progression-free survival for Phase II decision making
- 31 May 2011
- journal article
- research article
- Published by Elsevier BV in Contemporary Clinical Trials
- Vol. 32 (3), 446-452
- https://doi.org/10.1016/j.cct.2011.01.010
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor DynamicsJournal of Clinical Oncology, 2009
- On the Use of Change in Tumor Size to Predict Survival in Clinical Oncology Studies: Toward a New Paradigm to Design and Evaluate Phase II StudiesClinical Pharmacology & Therapeutics, 2009
- Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug DevelopmentCancer Cell, 2009
- Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2007
- Economics of New Oncology Drug DevelopmentJournal of Clinical Oncology, 2007
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II TrialJournal of Clinical Oncology, 2005
- Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial ResultsJournal of Clinical Oncology, 2002